Patent 8404830 was granted and assigned to SomaLogic, Inc. on March, 2013 by the United States Patent and Trademark Office.
The present disclosure is directed to the field of nucleic acid chemistry, specifically to 5-position modified uridines, as well as, oligonucleotides comprising said 5-position modified uridines. The present disclosure describes methods for producing aptamers comprising said 5-position modified uridines that are capable of binding to target molecules.